1. Introduction {#s0005}
===============

The elderly population is increasing globally, resulting in higher healthcare costs and demand for services ([@b0110], [@b0075]). The estimation of current statistics suggests that 2.9% of the affected elderly persons were more than 65 years of age in the Saudi population ([@b0150]). One of the challenges in the provision of healthcare to elderly persons is inappropriate prescriptions, drug-related is inappropriate prescriptions and complications. The earlier studies from the western population indicates 12% and 23% of more than 65 years of age consumed at least 10 medications at any given time, and five prescription drugs monthly ([@b0105]). One of the study from European population showed that the older people in community-dwelling received ∼2.8--5.0 drugs ([@b0035]). An earlier study in the 90s concluded the person who receives two, four and seven drugs experienced with 13%, 38% and 82% risk ([@b0085]). Duplicate use of drugs within the same class is common and often unrecognised. The side effects of drugs are leading to polypharmacy, coupled with continued prescription of cascades (example; prescribing levodopa for parkinsonian symptoms resulting from neuroleptic drugs side effects) ([@b0060]). Older individuals are at a higher risk of developing drug-related adverse events because of age-related changes and reduced organ reserve capacity ([@b0045]). Furthermore, age-related changes in drug pharmacokinetics and pharmacodynamics and coexisting diverse underlying medical morbidities contribute towards serious adverse drug interaction and toxicity ([@b0090]). Polypharmacy, non-prescription drugs and inadequate treatment adherence carry a substantially high risk for morbidity and mortality. Hospital admission, functional impairment, falls, cognitive decline, drug toxicity and poor quality of life are common, due to inappropriate prescription of medication ([@b0155], [@b0055], [@b0040]). In total, 5% of total hospitalisations are reportedly drug-related; 17% thereof are of older adults ([@b0115]).

Drug-related problems are common in primary care ([@b0065]) and up to 35% of older patients attending outpatient clinics develop preventable adverse drug interactions ([@b0120]). Prescription of inappropriate medications is an important preventable drug-related problem ([@b0030]). A potentially inappropriate medication (PIM) refers to prescription of drugs carrying risks outweighing the expected clinical benefits, especially when there is evidence for an equally or more effective and safer alternative medication ([@b0145], [@b0050]). There are few international evidence-based studies on a comprehensive clinical approach comprising appropriate drug prescription for elderly people. Beers' criteria, published in 1991 and updated in 2003 and 2012 ([@b0025], [@b0070], [@b0080]), are the most widely used tool for appropriate prescription and monitoring of elderly persons in ambulatory settings and long-term facilities. Recently, Beers' criteria updated PIMs to include up to 53 drugs in three classes, which may carry negative outcomes and limited effectiveness for elderly people. The criteria had been well described and emphasised, to improve the care of older adults and reduce exposure to PIMs ([@b0070]). PIMs fall under three major therapeutic classes, organs and systems, namely: PIMs and classes to avoid in older adults, PIMs and classes to avoid in older adults with certain diseases and syndromes and medications to be used with caution in older adults.

There is insufficient evidence regarding PIM use in primary care and home healthcare in Saudi Arabia. One economic-focused, cross-sectional study, conducted from 2002 to 2004, at Riyadh Military Hospital, using outpatients' pharmacy-dispensary records, found that 43.6%, 18% and 38.4% of patients took at least one, two and three or more PIMs, respectively ([@b0010]). Since there are limited qualitative and quantitative data locally on appropriate drug use among elderly persons, in ambulatory settings and home healthcare, the majority of prescriptions are by family physicians; improving the quality of family physicians' prescriptions would improve patients' quality of life and minimise drug hazards. Hence, we conducted this study, to identify and analyse the medications taken by elderly persons consulting family physicians at the Family and Community Medicine and the Home Healthcare departments at Prince Sultan Military Medical City, Riyadh, and to classify the dispensed drugs, based on Beers' criteria, as PIMs.

This study aimed to establish the extent of inappropriate drug prescription for and use by elderly patients, by determining the proportion of: (1) ambulatory medical care visits by elderly patients resulting in inappropriate drug prescription (visit-level analysis), and (2) elderly, community-dwelling recipients of inappropriate drugs (person-level analysis). Secondly, the study examined trends in these outcomes for recent years and, thirdly, factors associated with a higher risk of inappropriate drug prescription/use.

2. Materials and methods {#s0010}
========================

The target population was elderly patients, aged ⩾65 years, despite gender and ethnicity. Common medical co-morbidities possibly influencing the number of medications and pharmacokinetics, and the number of medications used by the elderly, were recorded. Only Prince Sultan Medical Military City (PSMMC) items and non-over--the-counter (non-OTC) medications were counted and registered for each patient. Non-PMMSC items, OTC medication and herbal supplements were excluded from the analysis, as they were not well recorded for each patient. We pooled and documented laboratory results possibly indicating functional impairment of common organs (renal function, liver function, uncontrolled diabetes, etc.) and increasing the potential hazards of some medications for each patient.

Data were collected from patients' medical electronic and non-electronic records, and from the main hospital laboratory framework. Data were captured and managed on EXCEL. Demographic data, a list of commonly used medications, comorbidities, laboratory data sheets and prescribed medication multiplicity were prepared and used by investigators.

All registered elderly patients who visited family medicine chronic disease clinics (CDCs) and those involved in the Home Health Care (HHC) programme were included in this study; institutionalised patients were excluded. 798n patients were randomly selected through the patient registry programme, from the data registries at Wazarat Family Medicine Center and Home Health clinics. We excluded patients attending other hospitals, with multiple medication prescriptions.

2.1. Statistical analysis {#s0015}
-------------------------

Data were analysed using an SPSS software programme (version 20). Both descriptive and analytic statistics were applied. Percentages, mean and standard deviation were used for descriptive statistics. For analytical statistics, Chi squared test was applied for categorical data, and Student's t test and ANOVA were applied for numerical data. Statistical significance was considered at *p* \< 0.05. The intended sample size was 400 participants. We used Beers' criteria due to their wide use in clinical practice; they are the best-known criteria for identifying PIM use among the elderly ([@b0125]). Evidence-based methodology enabled the development of the AGS 2012 Updated Beers' Criteria, to help healthcare providers improve medication safety in older adults. To determine the number of PIMs, we applied the latest criteria by Beers et al., published in 2012, and a review of scientific literature. Apart from explaining the drugs and doses to be avoided among elderly persons, to prevent adverse effects, these criteria evaluate the severity of potential adverse effects. We did not record treatment duration and indication of any inappropriate prescribed drugs, due to difficulties with data documentation.

3. Results {#s0020}
==========

The study participants were elderly, as defined by the World Health Organisation (WHO). The mean age was 75 years; with SD (75.2 ± 5.5) with no significant differences between CDC and HHC patients after using chi-square test. Female patients made up 62.2% of the sample. [Table 1](#t0005){ref-type="table"} and [Fig. 1](#f0005){ref-type="fig"} depict common chronic diseases among elderly participants. The majority of patients were diabetic (73.9%), hypertensive (83.2%) and with lipid profile abnormalities (73.8%). Almost all participants had haemoglobin abnormalities (99.2%), with no significant difference between CDC and HHCS patients. About 64% had some renal impairment.

[Table 2](#t0010){ref-type="table"} and [Fig. 2](#f0010){ref-type="fig"} depict the medication groups used by the patients. Iron supplements were the most commonly used (23.1%), followed by analgesics and opioids (17%). Different types of antipsychotics were used by 7.6% of the participants. Some patients were using two types of analgesic drugs (2%); few (0.1%) were using three types. Some patients (1%) were using two kinds of antipsychotics simultaneously.

Almost 52.5% of participants were using one or more PIMs as in [Table 3](#t0015){ref-type="table"}. At least 17.3% were using two; the majority were using \<4. One patient was using 10 PIMs simultaneously and another using 12.

Antispasmodics and muscle relaxants, tolterodine and chlorpheniramine, were frequently prescribed to 13 and 11 HHC patients respectively while two CDC patients were found to take tolterodine. Risperidone was one of the atypical antipsychotic medications prescribed to 39 HHC patients, and quetiapine to 29. Only one CDC patient was taking quetiapine. Other commonly prescribed medications were iron supplements (ferrous sulphate for 184 patients), oral muscle relaxants for 40 patients, hypoglycaemic (glibenclamide) for 49, diclofenac for 42 and tizanidine for 40. The most common PIM was a high dose of ferrous sulphate, in about 33% of the participants compared to the rest of the group (*p* \< 0.001). There was no statistical difference between the two patient groups regarding the use of paracetamol combinations (see [Table 4](#t0020){ref-type="table"}).

As in [Table 5](#t0025){ref-type="table"}, and based on Mann--Whitney *U* test results, liver function had no significant influence on prescription decisions. Only kidney function profile had some influence. Twelve PIMs were prescribed to patients, without adjustment of their renal impairment profile. Analgesics and opioids were the most common PIMs for patients with renal insufficiency. There was a statistically significant difference regarding prescription of iron supplements, between patients with normal kidney function and those with renal impairment.

4. Discussion {#s0025}
=============

Optimal drug therapy is essential in caring for elderly persons; worldwide, elderly patients use medication. A safe prescription method for elderly persons must include the decision as to whether a drug is indicated, choosing the best drug, determining a dose and schedule appropriate for the patient's physiologic status, monitoring for effectiveness and toxicity, educating the patient about expected side effects, and indications for seeking consultation. Polypharmacy and inappropriately prescribed drugs cause many adverse events and, sometimes, are life threatening. Side effects are serious consequences of inappropriate prescriptions. In our study, 52.5% of the 798 elderly, CDC and homecare patients were on ⩾1 PIMs, as per Beers' criteria. One to two and five or more PIMs were prescribed to approximately 30% and 6.8% of the participants, respectively. We found less prevalence of PIMs among elderly persons in this context in Saudi Arabia, than in some Western countries ([@b0095], [@b0135], [@b0100], [@b0020], [@b0140]).

The most common PIM was a high dose of ferrous sulphate (\>325 mg/day) among about 33% of the participants. This is due to the high prevalence of iron deficiency anaemia among the elderly. High dose of iron supplement may precipitate constipation, which in turn may induce abdominal pain, loss of appetite, frequent falls and social isolation. High iron doses were prescribed to 23% of surveyed patients, for no clear reason. This is problematic and predisposes participants to serious side effects. Analgesics and opioids were the second most prescribed medications, with ⩾1 type thereof taken by approximately 17%. According to previous studies, elderly patients require more analgesic prescriptions than do non-clinical adult populations ([@b0130]). This could be because elderly persons experience multiple medical problems and pain, due to chronic diseases like osteoarthritis, muscular pain, headaches and joint pains. Sometimes, a physician may not have sufficient skills to care for elderly patients or time to scrutinise patient history and physical examination, to determine the exact medical problem.

In this study, antipsychotic medications were the third most commonly prescribed drugs (8.6%). Despite the strong recommendation against prescription of antipsychotics to older patients, unless necessary, more than 69 patients received ⩾1 thereof. Anti-psychotic medications reportedly predispose elderly patients to falls, fractures, sleep problems and driving problems ([@b0005]). Scientific geriatric organisations warn physicians against prescribing antipsychotic drugs to elderly persons for periods exceeding four weeks, to avoid serious side effects. The United States Food and Drug Administration (FDA) cautions against prescription of antipsychotics to elderly persons, due to the increased risk of cardiovascular mortality resulting from chronic use ([@b0135]). Aspirin and clopidogrel were the least prescribed medications. The potential, serious side effects on the elderly include gastrointestinal upsets, gastric bleeding and bleeding disorders. The most common PIMs in our study were antipsychotics, tricyclic antidepressants, anticholinergics/muscle relaxants/antispasmodics, antiepileptics, sedative-hypnotics, antihypertensive, skeletal muscle relaxants, anti-infectives, oral hypoglycaemics, analgesics and opioids, platelet aggregation-inhibitors, antiarrhythmics, and iron supplements.

The possibility of an ADE should always be considered when evaluating elderly patients; any new symptom should be considered drug-related, until proven otherwise. Pharmacokinetic changes lead to increased plasma drug concentrations, and pharmacodynamic changes to increased drug sensitivity in older adults ([@b0015]). Various criteria have been introduced for identifying medications to avoid prescribing, or to prescribe cautiously, in older adults. Compliance with these is suboptimal. Clinicians could address this by avoiding overly prescribing inappropriate drug therapies. ADEs result in four times as many hospitalisations in elderly patients as in younger adults ([@b0005]). Prescription of cascades, drug--drug interactions and inappropriate drug doses result in preventable ADEs. Prescription of PIMs, as shown in this study, is a concern for elderly patients attending outpatient clinics and home residents; atypical antipsychotics, iron overdose, benzodiazepines and opioids are most commonly prescribed inappropriately. A step-wise approach towards prescriptions for older adults should include periodic review of current drug therapy; discontinuation of unnecessary medications; consideration of non-pharmacologic alternative strategies; consideration of safer, alternative medications; and prescription of the lowest possible effective dose and necessary beneficial medications only.
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###### 

Age, sex and medical history of homecare and CDC patients.

                                    Total (*n* = 798)   Homecare (*n* = 663)   CDC (*n* = 135)   *χ*^2^ test   *p*-Value                                                   
  --------------------------------- ------------------- ---------------------- ----------------- ------------- ------------------------------------------ ------- -------- ------------------------------------------
  *Age*                                                                                                                                                                    
  Mean ± SD                         75.2 ± 5.5          75.8 ± 5.4             72.2 ± 5.0        *t* = 7.067   \<0.001[⁎](#tblfn1){ref-type="table-fn"}                    
  Median (Q1--Q3)                   75 (71--79)         76 (72--80)            72 (68--76)                                                                                 
                                                                                                                                                                           
  *Gender*                                                                                                                                                                 
  Male                              302                 37.8                   238               35.9          64                                         47.4             
  Female                            496                 62.2                   425               64.1          71                                         52.6    6.317    0.012[⁎](#tblfn1){ref-type="table-fn"}
                                                                                                                                                                           
  *Disorders*                                                                                                                                                              
  Diabetes type 2 (DM2)             590                 73.9                   458               69.1          132                                        97.8    47.933   \<0.001[⁎](#tblfn1){ref-type="table-fn"}
  Hypertension (HTN)                664                 83.2                   552               83.3          112                                        83.0    0.007    0.933
  Dyslipidaemia                     589                 73.8                   467               70.4          122                                        90.4    23.053   \<0.001[⁎](#tblfn1){ref-type="table-fn"}
  Ischaemic heart disease (IHD)     136                 17.0                   121               18.3          15                                         11.1    4.044    0.044[⁎](#tblfn1){ref-type="table-fn"}
  Congestive heart failure (CHF)    31                  3.9                    22                3.3           9                                          6.7     3.368    0.066
  Dementia                          50                  6.3                    49                7.4           1                                          0.7     8.445    0.004[⁎](#tblfn1){ref-type="table-fn"}
  Parkinson's disease               37                  4.6                    36                5.4           1                                          0.7     5.578    0.018[⁎](#tblfn1){ref-type="table-fn"}
  Seizure disorders                 37                  4.6                    37                5.6           0                                          0.0     7.900    0.005[⁎](#tblfn1){ref-type="table-fn"}
  Psychiatric diseases              193                 24.2                   188               28.4          5                                          3.7     37.175   \<0.001[⁎](#tblfn1){ref-type="table-fn"}
  Renal function test abnormality   511                 64.0                   417               62.9          94                                         80.3    13.397   \<0.001[⁎](#tblfn1){ref-type="table-fn"}
  Liver function test abnormality   5                   0.6                    3                 0.2           2                                          1.5     Fisher   0.200
  Haemoglobin (Hb) abnormality      792                 99.2                   657               99.1          135                                        100.0   1.231    0.267

Statistically significant at *p* \< 0.05.

###### 

Frequency of use of PIMs by medication group (*n* = 798).

                                                     Frequency   Percentage
  -------------------------------------------------- ----------- ------------
  Anticholinergics/muscle relaxants/antispasmodics               
   1                                                 39          4.9
  Antipsychotics                                                 
   1                                                 61          7.6
   2                                                 8           1
  Antiepileptics                                                 
   1                                                 0           0.0
  Sedative-hypnotics                                             
   1                                                 6           0.8
  Antihypertensives                                              
   1                                                 12          1.5
  Antidepressants                                                
   1                                                 17          2.1
  Skeletal muscle relaxants                                      
   1                                                 43          5.4
  Anti-infectives                                                
   1                                                 2           0.3
  Oral hypoglycaemics                                            
   1                                                 49          6.1
  Analgesics and opioids                                         
   1                                                 119         14.9
   2                                                 16          2
   3                                                 1           0.1
  Platelet aggregation inhibitors                                
   1                                                 4           0.5
  Antiarrhythmics                                                
   1                                                 7           0.9
  Iron supplements                                               
   1                                                 184         23.1

###### 

Total number of PIMs among participants (*n* = 798).

  Total No. of medications   Frequency   Percentage
  -------------------------- ----------- ------------
  0                          379         47.5
  1                          103         12.9
  2                          138         17.3
  3                          54          6.8
  4                          69          8.6
  5                          23          2.9
  6                          17          2.1
  7                          3           0.4
  8                          9           1.1
  9                          1           0.1
  10                         1           0.1
  12                         1           0.1

###### 

Comparison of homecare and CDC patients' medication use.

                                       HHC (*n* = 663)   CDC (*n* = 135)   *χ*^2^ test   *p*-Value            
  ------------------------------------ ----------------- ----------------- ------------- ----------- -------- ------------------------------------------
  *Anticholinergic muscle relaxants*                                                                          
  Oxybutynin                           8                 1.2               0             0.0         Fisher   0.364
  Tolterodine                          13                2.0               0             0.0         Fisher   0.141
  Chlorpheniramine                     11                1.7               0             0.0         Fisher   0.227
  Hydroxyzine                          2                 0.3               0             0.0         Fisher   1.000
  Hyoscyamine                          1                 0.2               0             0.0         Fisher   1.000
  Scopolamine                          2                 0.3               2             1.5         Fisher   0.135
                                                                                                              
  *Antipsychotics*                                                                                            
  Quetiapine                           29                4.4               1             0.7         4.092    0.043[⁎](#tblfn2){ref-type="table-fn"}
  Haloperidol                          5                 0.8               0             0.0         Fisher   0.596
  Olanzapine                           3                 0.5               0             0.0         Fisher   1.000
  Risperidone                          39                5.9               0             0.0         8.349    0.004[⁎](#tblfn2){ref-type="table-fn"}
                                                                                                              
  *Sedative-hypnotics*                                                                                        
  Diazepam                             3                 0.5               0             0.0         Fisher   1.000
  Lorazepam                            3                 0.5               0             0.0         Fisher   1.000
  Antihypertensives:                                                                                          
  Methyldopa                           1                 0.2               1             0.7         Fisher   0.310
  Spironolactone \> 25 mg              9                 1.4               1             0.7         Fisher   1.000
                                                                                                              
  *Antidepressants*                                                                                           
  Fluoxetine                           4                 0.6               0             0.0         Fisher   1.000
  Clomipramine                         1                 0.2               0             0.0         Fisher   1.000
  Amitriptyline                        11                1.7               1             0.7         Fisher   0.702
                                                                                                              
  *Skeletal muscle relaxants*                                                                                 
  Tizanidine                           38                5.7               2             1.5         4.255    0.039[⁎](#tblfn2){ref-type="table-fn"}
  Baclofen                             3                 0.5               0             0.0         Fisher   1.000
                                                                                                              
  *Anti-infectives*                                                                                           
  Nitrofurantoin                       2                 0.3               0             0.0         Fisher   1.000
                                                                                                              
  *Oral hypoglycaemics*                                                                                       
  Glibenclamide                        42                6.3               7             5.2         0.257    0.612
                                                                                                              
  *Analgesics and opioids*                                                                                    
  Ibuprofen                            10                1.5               2             1.5         Fisher   1.000
  Diclofenac                           36                5.4               6             4.4         0.218    0.640
  Paracetamol combination              80                12.1              18            13.3        0.167    0.683
  Decongestant                         2                 0.3               0             0.0         Fisher   1.000
                                                                                                              
  *Platelet aggregation inhibitors*                                                                           
  Dipyridamole                         4                 0.6               0             0.0         Fisher   1.000
                                                                                                              
  *Antiarrhythmics*                                                                                           
  Digoxin \> 125 mcg                   7                 1.1               0             0.0         Fisher   0.609
                                                                                                              
  *Iron supplements*                                                                                          
  Ferrous sulphate \> 325 mg           175               26.4              9             6.7         24.607   \<0.001[⁎](#tblfn2){ref-type="table-fn"}

Statistically significant at *p* \< 0.05.

###### 

Comparison of the number of PIM groups used, based on renal function tests (RFT).

                                                     Normal Renal Function Test (n = 269)   Abnormal Renal Function Test (n = 511)   Mann--Whitney (*z*)   *p*                                                         
  -------------------------------------------------- -------------------------------------- ---------------------------------------- --------------------- ----- --- --- --- ----- ----- --- ---- --- --- --- -------- ------------------------------------------
  Anticholinergics/muscle relaxants/antispasmodics   0.1                                    0.2                                      0                     1     0   0   0   0.0   0.2   0   1    0   0   0   −1.226   0.220
  Antipsychotics                                     0.1                                    0.4                                      0                     2     0   0   0   0.1   0.3   0   2    0   0   0   −1.680   0.093
  Sedative-hypnotics                                 0.0                                    0.1                                      0                     1     0   0   0   0.0   0.1   0   1    0   0   0   −0.802   0.423
  Antihypertensives                                  0.0                                    0.1                                      0                     1     0   0   0   0.0   0.1   0   1    0   0   0   −0.527   0.598
  Antidepressants                                    0.0                                    0.1                                      0                     1     0   0   0   0.0   0.1   0   1    0   0   0   −0.071   0.944
  Skeletal muscle relaxants                          0.1                                    0.2                                      0                     1     0   0   0   0.1   0.2   0   1    0   0   0   −0.056   0.955
  Anti-infectives                                    0.0                                    0.0                                      0                     0     0   0   0   0.0   0.1   0   1    0   0   0   −1.027   0.305
  Oral hypoglycaemics                                0.0                                    0.2                                      0                     1     0   0   0   0.1   0.3   0   1    0   0   0   −1.520   0.129
  Analgesics and opioids                             0.2                                    0.5                                      0                     2     0   0   0   0.2   0.5   0   3    0   0   0   −1.139   0.255
  Platelet aggregation--inhibitors                   0.0                                    0.1                                      0                     1     0   0   0   0.0   0.0   0   1    0   0   0   −1.708   0.088
  Antiarrhythmics                                    0.0                                    0.1                                      0                     1     0   0   0   0.0   0.1   0   1    0   0   0   −1.266   0.206
  Iron supplements                                   0.4                                    0.5                                      0                     1     0   0   1   0.2   0.4   0   1    0   0   0   −6.909   \<0.001[⁎](#tblfn3){ref-type="table-fn"}
  Total No. medications                              1.7                                    2.0                                      0                     10    1   0   3   1.3   1.8   0   12   0   0   2   −3.209   0.001[⁎](#tblfn3){ref-type="table-fn"}

Statistically significant at *p* \< 0.05.
